Showing 2640 results
- Media Release /RATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
- Media Release /Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and…
- Media Release /New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with…
- Media Release /Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of…
- Story /
Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub
- Story /
- Featured News /
Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
- Media Release /In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…
- Story /
Researchers race to put hydroxychloroquine to the test in a large study.
- Story /
Explaining Chagas disease through the stories of patients in Bolivia.
Pagination
- ‹ Previous page
- 1
- …
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- …
- 264
- › Next page